Institution
University of South Florida
Education•Tampa, Florida, United States•
About: University of South Florida is a education organization based out in Tampa, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 34231 authors who have published 72644 publications receiving 2538044 citations. The organization is also known as: USF.
Topics: Population, Poison control, Cancer, Health care, Mental health
Papers published on a yearly basis
Papers
More filters
••
University of Massachusetts Amherst1, University of Toledo2, Miami University3, Food and Drug Administration4, Yale University5, University of Louisville6, University of Western Ontario7, Taipei Medical University8, University of Rochester9, University of South Florida10, Eli Lilly and Company11, United States Department of Agriculture12, University of Düsseldorf13, Harvard University14, College of the Holy Cross15, University of Colorado Boulder16, Michigan State University17, Indiana University18, Jilin University19, University of Texas Health Science Center at San Antonio20, University of Louisiana at Monroe21, McMaster University22, RTI International23, University of Florida24, Kansas State University25, University of California, Irvine26, University of Michigan27, Aarhus University28, North Carolina State University29, Stanford University30, Lovelace Respiratory Research Institute31, University of Wyoming32, University of Tasmania33, Binghamton University34, New York Medical College35, National Institutes of Health36
TL;DR: This article offers a set of recommendations that scientists believe can achieve greater conceptual harmony in dose-response terminology, as well as better understanding and communication across the broad spectrum of biological disciplines.
635 citations
••
Vanderbilt University1, Sarah Cannon Research Institute2, University of Chicago3, Duke University4, Heidelberg University5, Russian Academy6, Fox Chase Cancer Center7, Autonomous University of Barcelona8, Curie Institute9, City of Hope National Medical Center10, Bosch11, Aix-Marseille University12, University of South Florida13, Memorial Sloan Kettering Cancer Center14, Bristol-Myers Squibb15, Johns Hopkins University16, University of Duisburg-Essen17
TL;DR: Nivolumab provides long-term clinical benefit and a favorable tolerability profile compared with docetaxel in previously treated patients with advanced NSCLC and is reported on in a pooled analysis of the two studies.
Abstract: PurposeNivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials.gov identifier: NCT01673867) non–small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies.MethodsPatients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks). Minimum follow-up for survival was 24.2 months.ResultsTwo-year overall survival rates with nivolumab versus docetaxel were 23% (95% CI, 16% to 30%) versus 8% (95% CI, 4% to 13%) in squamous NSCLC and 29% (95% CI, 24% to 34%) versus 16% (95% CI, 12% to 20%) in nonsquamous NSCLC; relative reductions in the risk of death w...
635 citations
••
TL;DR: Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio.
Abstract: Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.
634 citations
••
TL;DR: This review briefly examines the current technologies available for enhanced microalgal CO(2) fixation, and specifically explores the possibility of coupling wastewater treatment with micro algal growth for eventual production of biofuels and/or added-value products, with an emphasis on productivity.
634 citations
••
TL;DR: Primary frameworks used in recent public health literature on the health of immigrant populations are discussed, gaps in this literature are noted, and a broader examination of immigration as both socially determined and a social determinant of health is argued.
Abstract: Although immigration and immigrant populations have become increasingly important foci in public health research and practice, a social determinants of health approach has seldom been applied in this area. Global patterns of morbidity and mortality follow inequities rooted in societal, political, and economic conditions produced and reproduced by social structures, policies, and institutions. The lack of dialogue between these two profoundly related phenomena-social determinants of health and immigration-has resulted in missed opportunities for public health research, practice, and policy work. In this article, we discuss primary frameworks used in recent public health literature on the health of immigrant populations, note gaps in this literature, and argue for a broader examination of immigration as both socially determined and a social determinant of health. We discuss priorities for future research and policy to understand more fully and respond appropriately to the health of the populations affected by this global phenomenon.
633 citations
Authors
Showing all 34549 results
Name | H-index | Papers | Citations |
---|---|---|---|
David J. Hunter | 213 | 1836 | 207050 |
Aaron R. Folsom | 181 | 1118 | 134044 |
John Hardy | 177 | 1178 | 171694 |
David Cella | 156 | 1258 | 106402 |
Arul M. Chinnaiyan | 154 | 723 | 109538 |
Andrew D. Hamilton | 151 | 1334 | 105439 |
Charles B. Nemeroff | 149 | 979 | 90426 |
C. Ronald Kahn | 144 | 525 | 79809 |
Alexander Belyaev | 142 | 1895 | 100796 |
Tasuku Honjo | 141 | 712 | 88428 |
Weihong Tan | 140 | 892 | 67151 |
Alison Goate | 136 | 721 | 85846 |
Peter Kraft | 135 | 821 | 82116 |
Xiaodong Wang | 135 | 1573 | 117552 |
Lars Klareskog | 131 | 697 | 63281 |